

SCOBERANA

Business Virtual Forum 2021

"Cuba and Germany. Possibilities for cooperation in the biotechnology sector"

German Office for the Promotion of Trade and Investment in Cuba Cuban Chamber of Commerce BioCubaFarma



MSc. Indira Utria Torres Business Specialist



A scientific institution honoring Dr. Carlos Juan Finlay



Closed Cycle Platform

R+D **Production** QA/QC **Clinical Evaluation Commercialization**

Pharmaceutical, biological, biotechnological and chemical synthesis preparations, mainly VACCINES



diseases vaccines

Infectious

Conjugate vaccines

Synthetic Vaccines

Combined vaccines

Active Pharmaceutical Ingredients






VA-MENGOC-BC[®]









Vaccine against meningococcal diseases
 Mass application in Cuba start in 1984

An excellent control of serogroup B meningitis

License in more than 17 countries, an apply to control outbreaks in Brazil, Colombia, Uruguay and Vietnam

More than 60 million doses apply in Latin-

America


WIPO Gold Medal Patent











Quimi-Hib[®]

□ Vaccine vs *Haemophilus influenzae* type b








- □ The first vaccine with a synthetic antigen produced and commercialized since 2004
- Synthetic chemistry to obtain Hib oligosaccharides has been become a competitive technology for conjugate vaccine production
- WIPO Gold Medal Patent 2005 WP 01/16146 USA, EPO, Australia, China.
- 2005 Award Tech Museum for Innovation







Cuban Immunization Program

COLLEMA NACIONAL DE VACUNACIÓN DE CUPA



- Against 13 diseases
- Vaccination
 coverage: More than
 98%

Y BIOTECNOLOGÍA

Population high immune level

Vacuna / Protege	Edad de la dosis				Dosis	-	Región de	Lugar de
	110	24	3**	Reactivación	(mi)	Via	aplicación	aplicación
BCG* / Tuberculosia	Al nacer				0,05	ID	Deltoides Izquierdo	Maternidad
Heberblovac H8*/ Hepatitis B	Al nacer				0,5	IM	1/3 medio de la cara antero - lateral del musio	Maternidad
Heberpenta-L /Difteria, Tosferina, Tétanos, Hepatitis B y Kaemophilus Influenzae Tipo B	2 m	4 m	6 m	18 m	0,5	IM	1/3 medio de la cara antero - lateral del musio. A los 18 M en el Deitoides	Policlinicos
VA-MENGOC-BC / Meningococo B y C	3 m	5 m		-	0,5	IM	1/3 medio de la cara antero - lateral del musio	Policlinicos
IPV / Poliomielitis	4 m	8 m		(0,1	ID	Deltoides Derecho	Policlinicos
DTP-VAC* / Difteria, Tétanos y Tosferina	2 m	4 m	6 m	18 m	0,5	IM	Deltoides	Policlinicos
Quimi-Hib* / Haemophilus Influenzae Tipo B.	2 m	4 m	6 m	18 m	0,5	IM	Deitoides	Policlinicos
PRS / Parotiditis, Rubéola y Sarampión	12 m			6 años	0,5	sc	Deltoides	Policlínicos y Escuelas
VA-DIFTET / Differia y Tétanos				6 años	0,5	IM	Deltoides	Escuelas
Vax-TYVI /Fiebre Titoidea	10 años			13 y 16 años	0,5	IM	Deitoides	Escuelas
Vax-TET / Tétanos	(14 años	0,5	IM	Deltoides	Escuelas
OPV / Poliomielitis	En campaña anual. Niños menores de tres años y 9 años.				2 gotas	Oral		Policlinicos y Consultorio

* Los hijos de madres positivas al antigeno de superficie de la Hepatitis B, se vacunarán con BCG a los 3 meses de nacidos. Se les aplicarán 4 dosis de vacuna de la Hepatitis B (al nacer, 1 mes, 2 meses y al año) y se reactivará a los 18 meses, con DPT y Hib. EL resto de las vacunas según el esquema.





Combined diphtheria, tetanus, cellular pertussis, hepatitis B and Haemophilus influenzae type b vaccine. Heberpenta was introduced in the Cuban's immunization program in September, 2006.

11 vaccines 8 - Cuba Production 6 - OUFFINITION Production









Projects

- Pneumococcal conjugate vaccine program
- Meningococcal meningitis vaccine program
- Pertussis conjugate vaccines
- Diarrheal vaccine program
- **Cancer vaccine program**

Quimi-Vio®




Against *Streptococcus Pneumoniae*

- □Heptavalent Conjugate Vaccine (serotypes 6B, 14, 18C, 19F, 23F, 1 and 5)
- **Cost-Effectiveness**
- **Tetanus Toxoid as carrier protein + AIPO4**
- **Over the analytical controls per batch**
- More than 20 clinical studies (Clinical Trials, surveillance studies, economic and impact evaluations studies)
- Current Status: Concluded Phase II-III Clinical Trials for children 1-5 years old
- **Ongoing Phase II-III Clinical Trials for infants**







STRATEGIC ALLIANCE AMONG BIOCUBAFARMA INSTITUTIONS AND MINISTRY OF CUBAN HEALTH





🔝 Cuba

SCOBERANA

SOBERANA®01

SC BERANA® 02

S©BERANA®Plus

Centro de Inmunología Molecular

VNIVERSIDAD DE LA HABANA

#CienciaCubana #CubaPorLaVida



BIOCUBAFARMA

MINISTERIO DE SALUD PÚBLICA

entiblica de Cuba



 $RBD + OMV + AI(OH)_3$

SIMILARITIES & DIFFERENCES



Subunit vaccine
 Receptor Binding Domain (RBD) of SARS-Cov-2 Coronavirus
 Storage conditions: 2-8 oC

SOBERANA®01SOBERANA®02 SOBERANA®Plus

RBD + Tetanus Toxoid + $AI(OH)_3$ RBD + $AI(OH)_3$

Unconjugated vaccine	Conjugate Vaccine	Booster vaccine Unconjugted vaccine
Healthy volunteers	Healthy volunteers	 ✓ Convalescents ✓ Volunteers with primary vaccination with other formulation









SC BERANA®01



□1st Cuban and Latin-American vaccine candidate vs SARS-CoV-2 virus included in the WHO draft



QWell kown and safety platform



Potential efficacty both infants and elderly population

Patent application submitted


Current Status: Concluded Phase I Clinical Trial. In process of approval Phase II-III Clinical Trials (adults) and Phase I-II Clinical Trials (pediatric population)





SC>BERANA®02







SC>BERANA®02



□1st and only conjugate vaccine vs SARS-CoV-2 virus in the world

2nd Cuban and Latin-American vaccine vs SARS-CoV-2 virus included in the WHO draft



□1st Cuban and Latin-American vaccine vs SARS-CoV-2 virus to begin Phase II and Phase III Clinical Trials



Well Known and safety platform





Innovative vaccine candidate. Patent application submited

Current Status: Ongoing Phase III Clinical Trial. In process of approval Phase I-II Clinical Trials (pediatric population)

Publications

CSH3 Cold Spring Haboratory	bio <mark>R</mark> χiv				
	THE PREPRINT SERVER FOR BIOLOGY				

SARS-CoV-2 RBD-Tetanus toxoid conjugate Comment en this vaccine induces a strong neutralizing immunity in preclinical studies

Yury Valdes-Balbin, Darietys Santana-Hederos, Lauren Quintero, Sonire Fernandez, Laura Rodriguez, Belinda Sanchez Ramirez, Rocimia Perez, Chudia Acosta Hang Mangaran, Belinda Santhez Ramirez, Rocimia Perez, Chudia Acosta Falix Cardoso, Hario Landys, Humberto Gonzalez, Milderg Farinas, Juliet Enriquez, Enrique Noa, Anamary Suarez, Cheng Fang, Luis A. Espinosa, Yassel Ramos, Luis Javier Gonzalez, Yanet Clament, Gerrunda Rojas, Fineto Relova, Yanoby Caherera, Julis Javier Gonzalez, Yanet Clament, Gerrunda Rojas, Erneto Relova, Yanoby Caherera,









SC BERANA® Plus










- Induces an important neutralizing response after a single dose
- Ist vaccine vs SARS-CoV-2 virus in convalescents registered with Phase I and Phase II Clinical Trials in the world
- Potential booster vaccine for protection vs mutant strains
- Patent aplication submitted
- Current status: Phase II Clinical Trial in Convalescents approved by CECMED
- As a booster vaccine with Soberana®02- Ongoing Phase II & III Clinical Trials

Publications









Cuba



Thank you!

www.finlay.edu.cu Contact person: Indira Utria Torres email: iutria@finlay.edu.cu



